Patents by Inventor Brent Atkinson

Brent Atkinson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6514514
    Abstract: Disclosed is a cartilage repair product that induces both cell ingrowth into a bioresorbable material and cell differentiation into cartilage tissue. Such a product is useful for regenerating and/or repairing both vascular and avascular cartilage lesions, particularly articular cartilage lesions, and even more particularly mensical tissue lesions, including tears as well as segmental defects. Also disclosed is a method of regenerating and repairing cartilage lesions using such a product.
    Type: Grant
    Filed: February 16, 1999
    Date of Patent: February 4, 2003
    Assignee: Sùlzer Biologics Inc.
    Inventors: Brent Atkinson, James J. Benedict
  • Patent number: 6511958
    Abstract: Disclosed is a cartilage repair product that induces both cell ingrowth into a bioresorbable material and cell differentiation into cartilage tissue. Such a product is useful for regenerating and/or repairing both vascular and avascular cartilage lesions, particularly articular cartilage lesions, and even more particularly mensical tissue lesions, including tears as well as segmental defects. Also disclosed is a method of regenerating and repairing cartilage lesions using such a product.
    Type: Grant
    Filed: February 16, 2000
    Date of Patent: January 28, 2003
    Assignee: Sulzer Biologics, Inc.
    Inventors: Brent Atkinson, James J. Benedict
  • Patent number: 6482594
    Abstract: Methods to obtain nucleic acid ligands that photocrosslink to target molecules associated with a disease state are provided. The methods presented are variations on the photoSELEX methods for obtaining nucleic acid ligands. In one method, a candidate mixture of photocrosslinkable nucleic acids is contacted with a biological substance obtained from a source associated with a disease state suspected of containing a target molecule to form nucleic acid-target molecule complexes, the complexes are irradiated to form crosslinked complexes, the photocrosslinked complexes are partitioned from the remainder of the candidate mixture; and the nucleic acid ligands that photocrosslink to molecule are retained. These nucleic acids are then contacted with a second biological substance of the same type as the first, but obtained from a source not associated with a disease state. This removes nucleic acids with affinity to molecules that are not associated with the disease state.
    Type: Grant
    Filed: June 14, 2001
    Date of Patent: November 19, 2002
    Assignee: SomaLogic, Inc.
    Inventors: Larry Gold, Michael Willis, Tad Koch, Steven Ringquist, Kirk Jensen, Brent Atkinson
  • Publication number: 20020106652
    Abstract: A method for identifying nucleic acid ligands to target molecules using the SELEX procedure. Nucleic acid candidate sequences contain photoreactive groups. After exposure of the nucleic acid sequences to the target molecule, nucleic acid-target molecule complexes are formed between nucleic acids having increased affinity to the target molecule and the target molecule. The complexes are irradiated such that photocrosslinks form between the photoreactive groups of the bound nucleic acids and the target molecule. The photocrosslinked complexes are separated from unbound nucleic acids, and the nucleic acids amplified to yield a ligand-enriched mixture of nucleic acids.
    Type: Application
    Filed: June 14, 2001
    Publication date: August 8, 2002
    Applicant: SomaLogic, Inc.
    Inventors: Larry Gold, Michael Willis, Tad Koch, Steven Ringquist, Kirk Jensen, Brent Atkinson
  • Patent number: 6291184
    Abstract: A method for identifying nucleic acid ligands to target molecules using the SELEX procedure wherein the candidate nucleic acids contain photoreactive groups and nucleic acid ligands identified thereby are claimed. The complexes of increased affinity nucleic acids and target molecules formed in the procedure are crosslinked by irradiation to facilitate separation from unbound nucleic acids. In other methods partitioning of high and low affinity nucleic acids is facilitated by primer extension steps as shown in the figure in which chain termination nucleotides, digestion resistant nucleotides or nucleotides that allow retention of the cDNA product on an affinity matrix are differentially incorporated into the cDNA products of either the high or low affinity nucleic acids and the cDNA products are treated accordingly to amplification, enzymatic or chemical digestion or by contact with an affinity matrix.
    Type: Grant
    Filed: December 13, 1999
    Date of Patent: September 18, 2001
    Assignee: SomaLogic, Inc.
    Inventors: Larry Gold, Michael Willis, Tad Koch, Steven Ringquist, Kirk Jensen, Brent Atkinson
  • Patent number: 6001577
    Abstract: A method for identifying nucleic acid ligands to target molecules using the SELEX procedure wherein the candidate nucleic acids contain photoreactive groups and nucleic acid ligands identified thereby are claimed. The complexes of increased affinity nucleic acids and target molecules formed in the procedure are crosslinked by irradiation to facilitate separation from unbound nucleic acids. In other methods partitioning of high and low affinity nucleic acids is facilitated by primer extension steps as shown in the figure in which chain termination nucleotides, digestion resistant nucleotides or nucleotides that allow retention of the cDNA product on an affinity matrix arc differentially incorporated into the cDNA products of either the high or low affinity nucleic acids and the cDNA products are treated accordingly to amplification, enzymatic or chemical digestion or by contact with an affinity matrix.
    Type: Grant
    Filed: June 8, 1998
    Date of Patent: December 14, 1999
    Assignee: NeXstar Pharmaceuticals, Inc.
    Inventors: Larry Gold, Michael Willis, Tad Koch, Steven Ringquist, Kirk Jensen, Brent Atkinson
  • Patent number: 5763177
    Abstract: A method for identifying nucleic acid ligands to target molecules using the SELEX pocedure wherein the candidate nucleic acids contain photoreactive groups and nucleic acid ligands identified thereby are claimed. The complexes of increased affinity nucleic acids and target molecules formed in the procedure are crosslinked by irradiation to facilitate separation from unbound nucleic acids. In other methods partioning of high and low affinity nucleic acids is facilitated by primer extension steps as shown in the figure in which chain termination nucleotides, digestion resistant nucleotides or nucleotides that allow retention of the cDNA product on an affinity matrix are differentially incorporated into the cDNA products of either the high or low affinity nucleic acids and the cDNA products are treated accordingly to amplification, enzymatic or chemical digestion or by contact with an affinity matrix.
    Type: Grant
    Filed: March 8, 1996
    Date of Patent: June 9, 1998
    Assignee: NeXstar Pharmaceuticals, Inc.
    Inventors: Larry Gold, Michael Willis, Tad Koch, Steven Ringquist, Kirk Jensen, Brent Atkinson